- Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
This study is looking into a new treatment for a type of bladder cancer called high-risk non-muscle invasive bladder cancer. It combines a drug called pembrolizumab with an existing treatment, BCG, to see if it works better and is safe.
For: High-risk Non-muscle Invasive Bladder CancerUnited States · Australia · Austria - RecruitingPHASE1
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
This study looks at a new medicine, PF-08052667, for a type of bladder cancer that hasn't spread into the muscle. It checks if the medicine works alone or with other treatments like BCG and sasanlimab, especially for cancer that has come back.
For: Non-muscle Invasive Bladder CancerUnited States · France · Israel - Active not recruitingPHASE3
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
This study looks at a new combination treatment for a type of early bladder cancer. It compares giving a standard treatment called BCG alongside a new drug called atezolizumab to just giving BCG alone. The aim is to see if the combination works better at preventing the cancer from coming back.
For: Bladder CancerBelgium · France · Spain - Not yet recruitingPHASE3
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
This study compares two ways to treat high-risk bladder cancer that hasn't spread: standard BCG therapy (a medicine put into the bladder) versus a combination of radiotherapy and a special drug to make it work better. It aims to find a more effective and reliable treatment.
For: High-Risk Non-Muscle Invasive Bladder CancerUnited Kingdom - RecruitingPHASE2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
This study explores a new treatment for aggressive bladder cancer that hasn't spread to the muscle. Researchers are testing if adding a new drug, intismeran autogene, to standard treatment (BCG) helps patients live longer without their cancer growing or returning. It's for adults with high-risk non-muscle invasive bladder cancer.
For: Urinary Bladder Neoplasms · Non-Muscle Invasive Bladder Neoplasms · Carcinoma in SituUnited States · Argentina · Australia